Avelas Biosciences
Biotechnology, N Torrey Pnes Rd, La Jolla, , 92037, California, 11099, United States, 11-50 Employees
Phone Number: 18*********
Who is AVELAS BIOSCIENCES
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of p...
Read More
-
Headquarters: 11099 N Torrey Pnes Rd, La Jolla, California, 92037, United States
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
Industry: Biotechnology
SIC Code: 8011
Does something look wrong? Fix it. | View contact records from AVELAS BIOSCIENCES
Avelas Biosciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Avelas Biosciences
Answer: Avelas Biosciences's headquarters are located at N Torrey Pnes Rd, La Jolla, , 92037, California, 11099, United States
Answer: Avelas Biosciences's phone number is 18*********
Answer: Avelas Biosciences's official website is https://avelasbio.com
Answer: Avelas Biosciences's revenue is $5 Million to $10 Million
Answer: Avelas Biosciences's SIC: 8011
Answer: Avelas Biosciences has 11-50 employees
Answer: Avelas Biosciences is in Biotechnology
Answer: Avelas Biosciences contact info: Phone number: 18********* Website: https://avelasbio.com
Answer: Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as AVB-620), a novel fluorescent imaging agent used in combination with a fluorescence camera system for real-time cancer detection and visualization during surgery. The goal of intraoperative image-guided surgery with pegloprastide is to increase the precision of cancer surgery and improve treatment outcomes for patients by fluorescently identifying cancer, in real-time during surgery, on the surfaces of excised tissue or residual cancer in the tumor bed not otherwise detected by surgeons and potentially left behind in a patient during an operation. In a prospective registration study in a broad population of women with primary, nonrecurrent breast cancer, use of pegloprastide during breast conserving surgery correctly identified cancer in up to 75% of women with positive margins who would have otherwise been candidates for a reoperation. Beyond breast cancer, Avelas has plans to explore the use of pegloprastide in a subset of other non-breast cancer surgeries, such as ovarian, colorectal, head and neck, melanoma, and sarcoma. Avelas has developed pegloprastide based on its molecular-delivery platform which uses the Companys proprietary Activatable Cell Penetrating Peptide (ACPP) technology and a tumors inherent pathological biochemistry to specifically target cancer tissue and deliver fluorescent cargo to tumors. The founding technology for Avelas was derived from the lab of 2008 Nobel Prize Laureate, Dr. Roger Y. Tsien at the University of California, San Diego. Pegloprastides structure, properties and ACPP delivery technology have been reported in eleven peer reviewed publications and have over 2,800 citations in other medical publications.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month